Monarch Partners Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Monarch Partners Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$2.03M	Buy	+45,479	New	+$1.62M	0.6%	82

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Monarch Partners Asset Management's CLDX Position: Q4 2022 in Review

Monarch Partners Asset Management opened a new position in Celldex Therapeutics (CLDX) in Q4 2022: 45,479 shares worth $2.03M. The stake represents 0.6% of the portfolio and ranks #82 among its holdings.

168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

Monarch Partners Asset Management held 45,479 shares of Celldex Therapeutics worth $2.03M as of Q4 2022.
Celldex Therapeutics was a new Monarch Partners Asset Management position in Q4 2022.
Celldex Therapeutics made up 0.6% of Monarch Partners Asset Management's portfolio in Q4 2022, its #82 holding.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.